ANUHPHRPharmaceuticals
Anuh Pharma Ltd — Cash Flow Statement
₹67.00
-2.77%
Anuh Pharma Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 16.98 Cr | 7.91 Cr | 52.35 Cr | 27.25 Cr | — |
| Capital Expenditure | -20.15 Cr | -5.02 Cr | -1.55 Cr | -1.61 Cr | — |
| End Cash Position | 19.56 Cr | 7.20 Cr | 1.93 Cr | 3.80 Cr | — |
| Beginning Cash Position | 7.20 Cr | 1.93 Cr | 3.80 Cr | 2.20 Cr | — |
| Changes In Cash | 12.36 Cr | 5.27 Cr | -1.87 Cr | 1.60 Cr | — |
| Financing Cash Flow | -4.86 Cr | -8.57 Cr | -12.29 Cr | -19.45 Cr | — |
| Interest Paid Cff | -0.48 Cr | -0.25 Cr | -0.12 Cr | -1.07 Cr | — |
| Cash Dividends Paid | -12.52 Cr | -10.03 Cr | -8.75 Cr | -7.56 Cr | — |
| Net Issuance Payments Of Debt | 8.48 Cr | 2.01 Cr | -3.11 Cr | -10.49 Cr | — |
| Net Short Term Debt Issuance | 8.48 Cr | 2.01 Cr | -3.11 Cr | -10.49 Cr | — |
| Investing Cash Flow | -19.91 Cr | 0.92 Cr | -43.48 Cr | -7.82 Cr | — |
| Interest Received Cfi | 1.41 Cr | 1.05 Cr | 0.78 Cr | 0.96 Cr | — |
| Dividends Received Cfi | 0.04 Cr | 0.09 Cr | 1.05 Cr | 1.35 Cr | — |
| Net Investment Purchase And Sale | -1.21 Cr | 4.79 Cr | -43.81 Cr | -8.66 Cr | — |
| Net PPE Purchase And Sale | -20.15 Cr | -5.02 Cr | -1.49 Cr | -1.47 Cr | — |
| Purchase Of PPE | -20.15 Cr | -5.02 Cr | -1.55 Cr | -1.61 Cr | — |
| Operating Cash Flow | 37.12 Cr | 12.93 Cr | 53.90 Cr | 28.86 Cr | — |
| Taxes Refund Paid | -11.12 Cr | -19.07 Cr | -13.47 Cr | -9.14 Cr | — |
| Change In Working Capital | -13.06 Cr | -43.58 Cr | 16.63 Cr | -8.99 Cr | — |
| Change In Other Current Liabilities | 0.05 Cr | 1.35 Cr | 2.25 Cr | 1.06 Cr | — |
| Change In Other Current Assets | -4.72 Cr | -10.69 Cr | 10.05 Cr | 15.54 Cr | — |
| Change In Payable | 17.73 Cr | -12.59 Cr | 32.22 Cr | 1.56 Cr | — |
| Change In Inventory | 0.92 Cr | -2.76 Cr | 7.29 Cr | 1.50 Cr | — |
| Change In Receivables | -27.05 Cr | -18.89 Cr | -35.18 Cr | -28.65 Cr | — |
| Other Non Cash Items | -1.80 Cr | -0.82 Cr | -0.23 Cr | -0.08 Cr | — |
| Provisionand Write Offof Assets | -0.98 Cr | 0.00 | -0.20 Cr | -0.05 Cr | — |
| Depreciation And Amortization | 8.74 Cr | 8.58 Cr | 9.70 Cr | 11.96 Cr | — |
| Depreciation | 8.74 Cr | 8.58 Cr | 9.70 Cr | 11.96 Cr | — |
| Pension And Employee Benefit Expense | -0.02 Cr | -0.05 Cr | 0.36 Cr | 0.40 Cr | — |
| Gain Loss On Investment Securities | -6.72 Cr | -10.82 Cr | -5.23 Cr | -3.99 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 0.12 Cr | 0.35 Cr | -0.86 Cr | — | — |
| Gain Loss On Sale Of PPE | -0.02 Cr | 0.00 | -0.01 Cr | -0.06 Cr | — |
| Net Income From Continuing Operations | 61.01 Cr | 78.31 Cr | 47.47 Cr | 39.12 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | -1000.00 | — | — | — |
| Common Stock Dividend Paid | — | -10.03 Cr | -8.75 Cr | -7.56 Cr | — |
| Sale Of PPE | — | — | 0.06 Cr | 0.14 Cr | 0.11 Cr |
| Net Other Financing Charges | — | — | — | -1000.00 | 0.02 Cr |
| Net Other Investing Changes | — | — | — | 1000.00 | — |
| Amortization Cash Flow | — | — | — | 0.06 Cr | 0.06 Cr |
| Repayment Of Debt | — | — | — | — | -30.96 Cr |
| Net Long Term Debt Issuance | — | — | — | — | -30.96 Cr |
| Long Term Debt Payments | — | — | — | — | -30.96 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Anuh Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.